128 related articles for article (PubMed ID: 38498796)
1. Epstein-Barr Virus BRLF1 Induces PD-L1 Expression in Nasopharyngeal Carcinoma Cells.
Wu CC; Chen MS; Lee TY; Huang TS; Cho DY; Chen JY
Viral Immunol; 2024 Mar; 37(2):115-123. PubMed ID: 38498796
[TBL] [Abstract][Full Text] [Related]
2. Natural Variations in BRLF1 Promoter Contribute to the Elevated Reactivation Level of Epstein-Barr Virus in Endemic Areas of Nasopharyngeal Carcinoma.
Zhang JB; Huang SY; Wang TM; Dong SQ; He YQ; Zheng XH; Li XZ; Wang F; Jianbing M; Jia WH
EBioMedicine; 2018 Nov; 37():101-109. PubMed ID: 30420297
[TBL] [Abstract][Full Text] [Related]
3. Expression of Epstein-Barr virus lytic gene BRLF1 in nasopharyngeal carcinoma: potential use in diagnosis.
Feng P; Ren EC; Liu D; Chan SH; Hu H
J Gen Virol; 2000 Oct; 81(Pt 10):2417-2423. PubMed ID: 10993929
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of nasopharyngeal carcinoma growth by RTA-expressing baculovirus vectors containing oriP.
Wang L; Shan L; Lo KW; Yin J; Zhang Y; Sun R; Zhong J
J Gene Med; 2008 Oct; 10(10):1124-33. PubMed ID: 18642396
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.
Wu CC; Chuang HY; Lin CY; Chen YJ; Tsai WH; Fang CY; Huang SY; Chuang FY; Lin SF; Chang Y; Chen JY
Mol Carcinog; 2013 Dec; 52(12):946-58. PubMed ID: 22641235
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
[TBL] [Abstract][Full Text] [Related]
7. EBV reactivation as a target of luteolin to repress NPC tumorigenesis.
Wu CC; Fang CY; Hsu HY; Chuang HY; Cheng YJ; Chen YJ; Chou SP; Huang SY; Lin SF; Chang Y; Tsai CH; Chen JY
Oncotarget; 2016 Apr; 7(14):18999-9017. PubMed ID: 26967558
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of IQGAP2 by EBV transactivator Rta and its influence on EBV life cycle.
Lin KM; Weng LF; Chen SJ; Lin SJ; Tsai CH
J Virol; 2023 Aug; 97(8):e0054023. PubMed ID: 37504571
[TBL] [Abstract][Full Text] [Related]
9. EBV Rta-induced IL-6 Promotes Migration of Bystander Tumor Cells Through IL-6R/JAK/STAT3 Pathway
Tung KL; Wu YT; Liu C; Lin SC; Wu CH; Wu SY; Chang Y; Lan YY
Anticancer Res; 2020 Jun; 40(6):3255-3264. PubMed ID: 32487620
[TBL] [Abstract][Full Text] [Related]
10. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
11. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
12. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation.
Xu FH; Xiong D; Xu YF; Cao SM; Xue WQ; Qin HD; Liu WS; Cao JY; Zhang Y; Feng QS; Chen LZ; Li MZ; Liu ZW; Liu Q; Hong MH; Shugart YY; Zeng YX; Zeng MS; Jia WH
J Natl Cancer Inst; 2012 Sep; 104(18):1396-410. PubMed ID: 22972969
[TBL] [Abstract][Full Text] [Related]
13. Sequence analysis of the Epstein-Barr virus (EBV) BRLF1 gene in nasopharyngeal and gastric carcinomas.
Jia Y; Wang Y; Chao Y; Jing Y; Sun Z; Luo B
Virol J; 2010 Nov; 7():341. PubMed ID: 21106109
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional activation of Epstein-Barr virus BRLF1 by USF1 and Rta.
Hung CC; Kuo CW; Wang WH; Chang TH; Chang PJ; Chang LK; Liu ST
J Gen Virol; 2015 Sep; 96(9):2855-2866. PubMed ID: 26297580
[TBL] [Abstract][Full Text] [Related]
15. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.
Fang W; Zhang J; Hong S; Zhan J; Chen N; Qin T; Tang Y; Zhang Y; Kang S; Zhou T; Wu X; Liang W; Hu Z; Ma Y; Zhao Y; Tian Y; Yang Y; Xue C; Yan Y; Hou X; Huang P; Huang Y; Zhao H; Zhang L
Oncotarget; 2014 Dec; 5(23):12189-202. PubMed ID: 25361008
[TBL] [Abstract][Full Text] [Related]
16. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
[TBL] [Abstract][Full Text] [Related]
17. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.
Wang J; Ge J; Wang Y; Xiong F; Guo J; Jiang X; Zhang L; Deng X; Gong Z; Zhang S; Yan Q; He Y; Li X; Shi L; Guo C; Wang F; Li Z; Zhou M; Xiang B; Li Y; Xiong W; Zeng Z
Nat Commun; 2022 Feb; 13(1):866. PubMed ID: 35165282
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
19. Enhancer infestation drives tumorigenic activation of inactive B compartment in Epstein-Barr virus-positive nasopharyngeal carcinoma.
Mizokami H; Okabe A; Choudhary R; Mima M; Saeda K; Fukuyo M; Rahmutulla B; Seki M; Goh BC; Kondo S; Dochi H; Moriyama-Kita M; Misawa K; Hanazawa T; Tan P; Yoshizaki T; Fullwood MJ; Kaneda A
EBioMedicine; 2024 Apr; 102():105057. PubMed ID: 38490101
[TBL] [Abstract][Full Text] [Related]
20. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
